Absci Corporation ABSI 深 沪
等待开盘 03-26 09:30:00 美东时间
2.92
-0.090
-2.99%
华盛通- 最 高3.11
- 今 开2.90
- 成交量 713.66万股
- 最 低 2.80
- 昨 收 3.01
- 总市值 4.38亿
- 52周最高 5.228
- 市盈率 静 --
- 换手率 4.76%
- 52周最低 2.0105
- 委 比 -84.70%
- 总股本 1.50亿
- 历史最高 31.53
- 量 比 1.30
- 振 幅 10.30%
- 历史最低 1.1111
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Blaize Holdings, Inc.涨53.15%，中阳金融集团涨36.70%
Blaize Holdings, Inc.涨53.15%；中阳金融集团涨36.70%；Next Technology涨35.00%
03-25 15:04
美股夜盘 | Blaize Holdings, Inc.涨59.46%，Next Technology涨36.00%
Blaize Holdings, Inc.涨59.46%；Next Technology涨36.00%；NFT金融控股涨27.60%
03-25 13:03
美股夜盘 | Blaize Holdings, Inc.涨55.86%，Next Technology涨28.00%
Blaize Holdings, Inc.涨55.86%；Next Technology涨28.00%；Braze, Inc. Class A涨20.09%
03-25 10:04
美股夜盘 | Blaize Holdings, Inc.涨48.65%，Next Technology涨35.00%
Blaize Holdings, Inc.涨48.65%；Next Technology涨35.00%；Braze, Inc. Class A涨19.42%
03-25 09:04
Absci Q4 EPS $(0.20), Inline, Sales $650.000K Miss $1.100M Estimate
Absci (NASDAQ:ABSI) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.25) per share from the same period last year. The company
03-25 04:08
Absci targets Q4 2026 start for Phase 2 ABS-201 endometriosis trial
Absci targets Q4 2026 start for Phase 2 ABS-201 endometriosis trial Absci announced the launch of an endometriosis advisory board to guide the clinical research program for ABS-201, an anti-prolactin receptor antibody in clinical development for endometriosis. The company said it anticipates initiat
03-24 20:05
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic
Absci Corporation launches an endometriosis advisory board for its ABS-201 program, a novel antibody targeting a non-hormonal pathway. The board includes leading experts from Yale, UCSF, and Mayo Clinic. ABS-201 aims to treat endometriosis without suppressing fertility, addressing an unmet need. The company plans to initiate Phase 2 trials in Q4 2026.
03-24 12:00
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Needham Reiterates Buy on Absci, Maintains $7 Price Target
Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $7 price target.
03-18 18:50
